Healthcare Equipment and Supplies
Company Overview of Immunetics, Inc.
Immunetics, Inc., a biotechnology company, researches and develops immunoassay and molecular probe kits and instruments for the diagnosis of infectious diseases. Its products include Miniblotter instrument system for western blot, spoligotyping, and various multi-probe membrane assays; cell adhesion flow chamber for cell-cell interaction studies; and C6 peptide Lyme ELISA, a synthetic peptide ELISA test for Lyme disease anthrax. The company’s products also include QuickELISA, a blood test for anthrax infection; and QualiCode western blot assays for diseases where diagnosis is challenging. In addition, it offers QuickELISA Anthrax-PA kit, an in vitro diagnostic test for the detection of antib...
27 Drydock Avenue
Boston, MA 02210
Founded in 1987
Key Executives for Immunetics, Inc.
Chief Executive Officer and Director
Vice President of Finance
Quality Assurance and Quality Control Director
Compensation as of Fiscal Year 2014.
Immunetics, Inc. Key Developments
Immunetics Introduces Updated BacTx Analyzer for Use with its BacTx Rapid Test for Bacterial Contamination of Platelets
Oct 14 13
Immunetics, Inc. introduced the updated BacTx(R) Analyzer for use with its BacTx rapid test for bacteria in whole-blood derived and apheresis platelets. The Analyzer offers automated interpretation, tracking, and documentation -- features that not only increase transfusion patient safety, but also provide seamless integration with the laboratory workplace. The BacTx assay gives hospitals and blood banks a practical tool for assuring the safety of their platelets. The colorimetric assay can detect aerobic, anaerobic, gram-negative and gram-positive bacteria in a single test. The test is designed to enable testing closer to time of transfusion, to reduce the risk of transfusing contaminated platelets. The updated BacTx Analyzer delivers a faster turnaround of results and a host of new automation and workflow-enhancement features. Complete assay results and analysis are delivered within 30 minutes. STAT, control, and standard assay capabilities allow for testing flexibility. Designed for simple, easy integration, the BacTx Analyzer fits seamlessly into the existing workflow of any laboratory or transfusion center.
Immunetics, Inc. Receives U.S. Food and Drug Administration Clearance for its BacTx(R) Rapid Test for Bacteria in Apheresis Platelets
Aug 15 13
Immunetics, Inc. has received U.S. Food and Drug Administration (FDA) clearance for its BacTx(R) rapid test for bacteria in apheresis platelets. The BacTx system is a colorimetric assay that can detect aerobic, anaerobic, gram-negative and gram-positive bacteria in a single test. The BacTx assay combines high sensitivity with simple, easy workflow integration. It utilizes a patented, highly specific, universal bacterial detection reagent that has been shown to detect wild and cultured bacterial strains. BacTx is intended for use as a point-of-issue test performed at the transfusion site on the day of issue. The BacTx assay can be used for quality control testing of: Leukocyte-reduced apheresis platelets (LRAP) within 24 hours of transfusion, following testing with an FDA-cleared growth-based bacterial detection device. Pools of up to six units of leukocyte-reduced whole-blood derived platelets that are pooled within 4 hours of transfusion.
Immunetics, Inc. Announces Executive Changes
Nov 26 12
Immunetics, Inc. announced that the company's Board of Directors has appointed John Yonkin as Chief Executive Officer. Mr. Yonkin will assume the post of CEO effective December 1, 2012. He will also serve as a member of the Board of Directors. Mr. Yonkin succeeds Dr. Andrew Levin, the company's founder. Dr. Levin will remain President at Immunetics and will continue to lead the Research and Development group.
Similar Private Companies By Industry
Recent Private Companies Transactions
February 26, 2014